Interferon-gamma (IFN-γ) is a pleiotropic cytokine critical for innate and adaptive immunity, primarily produced by activated T cells (especially Th1 cells) and natural killer (NK) cells. It plays a central role in combating intracellular pathogens, regulating immune responses, and modulating tumor surveillance. IFN-γ binds to its receptor (IFNGR), triggering JAK-STAT signaling pathways that induce expression of genes involved in antigen presentation, macrophage activation, and antimicrobial defense.
Antibodies targeting IFN-γ (IFN-γ antibodies) are essential tools in research and diagnostics. Monoclonal antibodies (mAbs) are widely used to neutralize IFN-γ activity in vitro and in vivo, helping elucidate its functions in immune regulation, autoimmune diseases (e.g., rheumatoid arthritis), and infectious disorders (e.g., tuberculosis). Polyclonal antibodies are employed in immunoassays (ELISA, Western blot, flow cytometry) to detect IFN-γ levels in biological samples, aiding in disease biomarker studies. Additionally, IFN-γ autoantibodies, found in rare immunodeficiencies, are linked to susceptibility to infections like disseminated mycobacterial disease.
Therapeutic applications of IFN-γ antibodies are under exploration, particularly in dampening excessive IFN-γ-driven inflammation or enhancing antitumor immunity. However, their clinical use requires careful balancing due to IFN-γ’s dual role in both host defense and pathological inflammation. Advances in antibody engineering (e.g., humanized mAbs) continue to refine their specificity and therapeutic potential.